Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda scores in frontline lung cancer yet again

Merck’s Keytruda scores in frontline lung cancer yet again

NSCLC, including those with both squamous and non-squamous types and a full range of PD-L1 expression levels from 1% and above. ... are both hoping to find a role for combinations pairing PD-1/PD-L1 inhibitors with CTLA4 inhibitors.

Latest news

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    BMS is also partnered with Incyte on a trial of its PD-1 inhibitor Opdivo (nivolumab) with epacadostat, as is AstraZeneca with its PD-L1 blocker Imfinzi (durvalumab), so the blow ... That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined

  • AZ pushes back data read-out from MYSTIC lung cancer trial AZ pushes back data read-out from MYSTIC lung cancer trial

    questions about the validity of combining PD-1/PD-L1 and CTLA4 inhibitors in these patients. ... TMB differs from the usual PD-L1 expression biomarker used in trials of PD-1/PD-L1 inhibitors and has been proposed as a superior option for immuno-oncology

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The company is maintaining its lead in the PD-1/PD-L1

  • Merck buys cancer-killing virus firm Viralytics for $394m Merck buys cancer-killing virus firm Viralytics for $394m

    wave of PD-1 and PD-L1 inhibitors, which are already pulling in billions of dollars in sales but don’t work in a sizeable proportion of patients. ... One potentially interested party could be Bristol-Myers Squibb, which makes rival PD-1 inhibitor

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    With five drugs targeting PD-1 or PD-L1 already on the market Sanofi and Regeneron are set to be very late entrants into the category, and have chosen an indication ... L1 inhibitors gaining momentum.

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response, ”says Xuan.

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics